MAPK8 and cancer: Based on the western blot data, we decided to employ various MAP kinase inhibitors, i.e., SB203580 (p38 MAP kinase inhibitor), selumetinib (ERK1/2 or MEK1 inhibitor) and SP600125 (JNK inhibitor), to investigate whether specific MAP kinase activity is associated with the compound effects on anti-TNBC cell proliferation and/or the induction of cancer cell cytoplasmic vacuolation and cell death.